Document text
Principal Investigator: Haian Fu
Organization: EMORY UNIVERSITY
Fiscal Year: 2024
Award: $782,142
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
The World Health Organization (WHO) declared Mpox (MPX) a global health emergency in 2022 and in the
United States, MPX was declared a Public Health Emergency with >30,500 cases confirmed so far. MPX is a
zoonotic infectious disease caused by the orthopoxvirus Mpox virus (MPXV), which is related to the virus that
causes smallpox. Vaccination against smallpox offers protection against MPXV; however, routine smallpox
vaccination ended in 1972 in US and 1984 world-wide following the successful global eradication of smallpox in
1979. Hence, most of the world’s population is highly vulnerable. In March-June 2023, 40 Mpox cases were
identified in Chicago, including many vaccinated patients, suggesting decreased vaccine effectiveness.
There are currently no FDA-approved drugs for MPX. There is an Expanded Access Investigational New Drug
(EA-IND) Protocol for use of tecovirimat (TPOXX), which targets VP37, a viral protein involved in the
envelopment of intracellular mature virus. Cidofovir (CDV) and its lipid pro-drug brincidofovir have been reported
to also inhibit multiple orthopoxviruses, albeit with reduced potency relative to their activity against herpesviruses.
There are several reports that establish that the barriers to resistance for TOPXX and CDV are low. Hence, there
is a lack of efficacious, well-tolerated drugs that can be broadly used for the treatment and prevention of MPXV
infections. To address this public health challenge our multidisciplinary team will extend long standing
collaborative efforts on other infectious diseases towards the discovery of innovative antivirals that target MPXV.
This strategy is designed to leverage exceptional expertise in drug discovery, nucleoside chemistry, assay
development, screening technologies, and mechanism of action studies, augmented by the expertise at the CDC.
We hypothesize that direct antiviral agents (DAA) against MPXV can be efficiently discovered through
informative assays for high throughput screening (HTS) and high content screening (HCS) and validated, thus
leading into downstream lead candidate development. To address this hypothesis, we propose experiments that
address the following aims:
Specific Aim 1. To further develop and optimize antiviral assays
Specific Aim 2. To implement screening campaigns for the discovery of low cytotoxicity antiviral hits
Specific Aim 3. To determine the mechanisms of action and resistance (MOA and MOR) of select hits
Specific Aim 4. To optimize potent, broad-spectrum, non-cytotoxic hits and identify a clinical candidate
Given the team’s preliminary data, outstanding expertise, access to world-class state-of-the-art screening
facilities (including BSL-3 labs), and the contributions to development of drugs for the treatment of HIV, HBV,
HCV, and SARS-CoV-2 in humans, we expect to generate compound leads that can progress rapidly to
advanced preclinical development.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Africa><Anti-HIV Positivity><Anti-viral Agents><Assay><Attenuated><Binding Sites><Bioassay><Biological Assay><Biology><CMV><COVID-19 virus><COVID19 virus><Case Study><Cell Body><Cell Culture Techniques><Cells><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Central Africa><Chemicals><Chemistry><Chicago><Cidofovir><Clinical><CoV-2><CoV2><Collection><Combining Site><Communicable Diseases><Containment><Country><Cytomegalovirus><DNA-Dependent RNA Polymerases><DNA-Directed RNA Polymerase><Data><Development><Disease Outbreaks><Dose><Drug Precursors><Drug Targeting><Drug Therapy><Drugs><Engineering><FDA approved><Food and Drug Administration><Future><Gene Targeting><Goals><Golgi><Golgi Apparatus><Golgi Complex><HBV><HCMV><HCV><HIV><HIV Positive><HIV Positivity><HIV Seroconversion><HIV Seropositivity><HIV antibody positive><HPMPC><HSV><HTLV-III Seroconversion><HTLV-III Seropositivity><Hepatitis B Virus><Hepatitis C virus><Herpes Simplex Virus><Herpes labialis Virus><Herpesviridae><Herpesviruses><High Throughput Assay><Homologous Serum Hepatitis Virus><Human><Human Immunodeficiency Viruses><Immunodiagnostics><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Investigational Drugs><Investigational New Drugs><LAV-HTLV-III><Lead><Libraries><Ligands><Lipids><Lymphadenopathy-Associated Virus><Lytotoxicity><Medication><Medicinal Chemistry><Membrane><Modern Man><Modified Vaccinia Ankara><Modified Vaccinia Virus Ankara><Monkey Pox><Monkey Pox Virus><Monkeypox><Monkeypox virus><Monkeypoxvirus><Nucleosides><Orthopox virus><Orthopoxvirus><Outbreaks><Pathology><Patients><Pb element><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacology><Pharmacotherapy><Population><Poxviridae><Poxvirus officinale><Poxviruses><Prevention><Pro-Drugs><Process><Prodrugs><Proteomics><Protocol><Protocols documentation><Public Health><RNA Polymerases><Reactive Site><Reporter><Reporting><Resistance><Ribonucleosides><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Salivary Gland Viruses><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Simplexvirus><Smallpox><Speed><Structure><Structure-Activity Relationship><Technology><Tenofovir><Testing><Therapeutic><USFDA><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States Food and Drug Administration><Vaccination><Vaccinee><Vaccines><Vaccinia virus><Validation><Variola><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Genes><Viral Proteins><Viread><Virus><Virus Diseases><Virus Inhibitors><Virus Replication><Virus-HIV><World Health Organization><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><adefovir><analog><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><assay development><attenuate><attenuates><case report><cell culture><cell cultures><chemical structure function><clinical candidate><community spread><community transmission><community-level spread><community-level transmission><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytomegalovirus group><cytotoxicity><data deposition><data submission><design><designing><developmental><drug development><drug discovery><drug repositioning><drug repurposing><drug treatment><drug/agent><experiment><experimental research><experimental study><experiments><global health emergency><hCoV19><heavy metal Pb><heavy metal lead><herpes virus><high risk group><high risk individual><high risk people><high risk population><high throughput screening><immunological diagnostics><improved><innovate><innovation><innovative><lead candidate><membrane structure><meter><miniaturize><miniaturized><mpox><mpox virus><mpxv><multidisciplinary><mutant><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathogen><pox virus><pre-clinical development><preclinical development><protein structure><protein structures><proteins structure><public health emergency><recombinant vaccinia virus><repurposing agent><repurposing medication><resistance mutation><resistant><resistant mutation><reverse genetics><screening><screenings><small pox><small pox eradication><smallpox eradication><structure function relationship><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine effectiveness><validation studies><validations><variola major><vector><viral infection><viral inhibitor><viral multiplication><viral replication><virology><virtual screening><virtual screenings><virus infection><virus multiplication><virus protein><virus-induced disease>